| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 177 | 1.480 | - | 15.684 | 26.106 | 11.364 | 14.466 | 25.082 | 22.750 | 37.313 |
| Total Income - EUR | 177 | 1.480 | - | 15.684 | 26.106 | 13.682 | 14.466 | 25.082 | 22.750 | 37.313 |
| Total Expenses - EUR | 0 | 1.431 | - | 14.676 | 19.887 | 13.604 | 14.129 | 24.807 | 22.386 | 34.184 |
| Gross Profit/Loss - EUR | 177 | 48 | - | 1.007 | 6.220 | 78 | 337 | 275 | 365 | 3.129 |
| Net Profit/Loss - EUR | 171 | 7 | - | 851 | 5.959 | 4 | 337 | 92 | 137 | 3.023 |
| Employees | 0 | 0 | - | 2 | 2 | 2 | 1 | 1 | 2 | 2 |
Check the financial reports for the company - Criazolex Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 48 | - | 46 | 1.083 | 565 | 290 | 73 | 0 | 978 |
| Current Assets | 222 | 237 | - | 2.046 | 6.943 | 7.460 | 7.894 | 8.428 | 8.813 | 10.636 |
| Inventories | 0 | 0 | - | 0 | 0 | 99 | 684 | 686 | 684 | 2.493 |
| Receivables | 177 | 0 | - | 13 | 13 | 316 | 16 | 16 | 16 | 353 |
| Cash | 45 | 237 | - | 2.034 | 6.931 | 7.046 | 7.194 | 7.725 | 8.113 | 7.791 |
| Shareholders Funds | 216 | 221 | - | 1.502 | 7.432 | 7.295 | 7.469 | 7.585 | 7.699 | 10.678 |
| Social Capital | 45 | 45 | - | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 5 | 64 | - | 591 | 594 | 730 | 714 | 916 | 1.114 | 936 |
| Income in Advance | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8559 - 8559" | |||||||||
| CAEN Financial Year |
9329
|
|||||||||
Comments - Criazolex Srl